van den Berg R, Slim C L, Lutgers Helen L, de Heide L J M, Wolthuis A
Medisch Centrum Leeuwarden, afd. Interne Geneeskunde, Leeuwarden.
Contact: R. van den Berg (
Ned Tijdschr Geneeskd. 2018 Feb 14;162:D2358.
Supraphysiological doses of biotin are being tested in patients with multiple sclerosis. Biotin can cause interference with laboratory assessment of thyroid function, and therefore give a false suggestion of thyrotoxicosis.
A 64-year-old patient was referred for assessment of thyrotoxicosis, due to Graves' disease. Antithyroid medication was started, but there was no effect on laboratory results. In addition, he developed symptoms which subsequently could be attributed to iatrogenic hypothyroidism. Biotin interference, when assaying TSH and thyroxin, was suspected. Upon further investigation, the patient revealed to use high doses of biotin. After discontinuation of the biotin treatment, the thyroid function test normalized.
It is expected that in the future, patients with multiple sclerosis will use biotin more often. Therefore, it is important for healthcare professionals to be aware that biotin can interfere with immunoassays for thyroid hormones, to avoid misdiagnosis and unnecessary treatment for hyperthyroidism.
超生理剂量的生物素正在多发性硬化症患者中进行测试。生物素会干扰甲状腺功能的实验室评估，从而给出甲状腺毒症的错误提示。
一名64岁的患者因格雷夫斯病被转诊以评估甲状腺毒症。开始使用抗甲状腺药物，但对实验室结果没有影响。此外，他出现了随后可归因于医源性甲状腺功能减退的症状。怀疑在检测促甲状腺激素（TSH）和甲状腺素时存在生物素干扰。进一步调查后，患者透露使用了高剂量的生物素。停止生物素治疗后，甲状腺功能测试恢复正常。
预计未来，多发性硬化症患者将更频繁地使用生物素。因此，医疗保健专业人员必须意识到生物素会干扰甲状腺激素的免疫测定，以避免甲状腺功能亢进症的误诊和不必要的治疗，这一点很重要。
